Biohaven Pharmaceutical Holding Co (BHVN) – Analysts’ Recent Ratings Updates

Several analysts have recently updated their ratings and price targets for Biohaven Pharmaceutical Holding Co (NASDAQ: BHVN):

  • 10/5/2017 – Biohaven Pharmaceutical Holding Co was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating.
  • 10/3/2017 – Biohaven Pharmaceutical Holding Co had its price target lowered by analysts at Needham & Company LLC from $43.00 to $36.00. They now have a “buy” rating on the stock.
  • 10/3/2017 – Biohaven Pharmaceutical Holding Co had its “overweight” rating reaffirmed by analysts at Morgan Stanley. They now have a $38.00 price target on the stock, down previously from $47.00.
  • 10/3/2017 – Biohaven Pharmaceutical Holding Co had its “outperform” rating reaffirmed by analysts at William Blair.
  • 9/28/2017 – Biohaven Pharmaceutical Holding Co was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 9/25/2017 – Biohaven Pharmaceutical Holding Co had its price target raised by analysts at Morgan Stanley from $28.00 to $47.00. They now have an “overweight” rating on the stock.
  • 9/20/2017 – Biohaven Pharmaceutical Holding Co was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 9/13/2017 – Biohaven Pharmaceutical Holding Co had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $43.00 price target on the stock, up previously from $30.00.
  • 9/12/2017 – Biohaven Pharmaceutical Holding Co had its “buy” rating reaffirmed by analysts at Piper Jaffray Companies. They now have a $54.00 price target on the stock.
  • 9/8/2017 – Biohaven Pharmaceutical Holding Co was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “
  • 9/7/2017 – Biohaven Pharmaceutical Holding Co was upgraded by analysts at BidaskClub from a “buy” rating to a “strong-buy” rating.
  • 8/28/2017 – Biohaven Pharmaceutical Holding Co was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “
  • 8/22/2017 – Biohaven Pharmaceutical Holding Co was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “
  • 8/16/2017 – Biohaven Pharmaceutical Holding Co was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Biohaven Pharmaceutical Holding Company Ltd. is a biopharmaceutical company. It focuses on the identification and development of orphan neurologic indications and other neurological pathways. The company’s pipeline includes BHV-0223, which is a formulation of a glutamate-modulating agent; BHV-4157, which is a new chemical entity that modulates glutamate and BHV-5000, which is an in-licensed investigational agent of the Company targeting N-Methyl-D-Aspartate receptor antagonism which are in clinical trial stage. Biohaven Pharmaceutical Holding Company Ltd. is based in NEW HAVEN, United States. “

Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) opened at 33.04 on Wednesday. The firm’s 50-day moving average is $36.17 and its 200 day moving average is $27.87. The stock’s market capitalization is $1.19 billion. Biohaven Pharmaceutical Holding Co Ltd has a 12-month low of $17.00 and a 12-month high of $39.51.

Biohaven Pharmaceutical Holding Company Ltd. is a United States-based biopharmaceutical company. The Company is engaged in the identification and development of clinical-stage compounds targeting orphan neurologic indications and other neurological pathways. It has a portfolio of multiple late-stage drug candidates.

Receive News & Ratings for Biohaven Pharmaceutical Holding Co Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biohaven Pharmaceutical Holding Co Ltd and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply